Enasidenib-Induced Differentiation Syndrome in IDH2-Mutant Acute Myeloid Leukemia

被引：5
|
作者：
Patel, Shyam A. [1 ,2 ]
机构：
[1] Stanford Univ, Dept Med, Div Hematol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Div Oncol, Stanford Canc Inst,Sch Med, Stanford, CA 94305 USA
来源：
JAMA ONCOLOGY | 2018年 / 4卷 / 08期
关键词：
MUTATIONS;
D O I：
10.1001/jamaoncol.2017.4724
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1110 / +
页数：3
相关论文
共 50 条
  • [21] Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients With Previously Untreated Mutant-IDH2 Acute Myeloid Leukemia
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 16 - 17
  • [22] Loculated Pleural Effusion Due to Differentiation Syndrome in a Patient With Acute Myeloid Leukemia on Enasidenib
    Yang, M. M.
    Kakol, M.
    Kumar, S. I.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [23] Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
    Daniel A. Pollyea
    Martin S. Tallman
    Stéphane de Botton
    Hagop M. Kantarjian
    Robert Collins
    Anthony S. Stein
    Mark G. Frattini
    Qiang Xu
    Alessandra Tosolini
    Wendy L. See
    Kyle J. MacBeth
    Samuel V. Agresta
    Eyal C. Attar
    Courtney D. DiNardo
    Eytan M. Stein
    Leukemia, 2019, 33 : 2575 - 2584
  • [24] Enasidenib Monotherapy Is Effective and Well-Tolerated in Patients with Previously Untreated Mutant-IDH2 (m IDH2) Acute Myeloid Leukemia (AML)
    Pollyea, Daniel A.
    Tallman, Martin S.
    De Botton, Stephane
    DiNardo, Courtney D.
    Kantarjian, Hagop M.
    Collins, Robert H.
    Stein, Anthony S.
    Xu, Qiang
    Tosolini, Alessandra
    Gupta, Ira
    Agresta, Samuel V.
    Stein, Eytan M.
    BLOOD, 2017, 130
  • [25] Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia
    Pollyea, Daniel A.
    Tallman, Martin S.
    de Botton, Stephane
    Kantarjian, Hagop M.
    Collins, Robert
    Stein, Anthony S.
    Frattini, Mark G.
    Xu, Qiang
    Tosolini, Alessandra
    See, Wendy L.
    MacBeth, Kyle J.
    Agresta, Samuel, V
    Attar, Eyal C.
    DiNardo, Courtney D.
    Stein, Eytan M.
    LEUKEMIA, 2019, 33 (11) : 2575 - 2584
  • [26] Enasidenib for Relapsed/Refractory Acute Myeloid Leukemia With IDH2 Meutations: Optimizing the Patient Experience
    Roboz, Gail J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 322 - 322
  • [27] Enasidenib for the treatment of acute myeloid leukemia
    Dugan, James
    Pollyea, Daniel
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2018, 11 (08) : 755 - 760
  • [28] Enasidenib, an Oral Therapy in Mutant IDH2 Relapsed/Refractory Acute Myeloid Leukemia: A Real-Life Single Center Experience
    Riva, Marta
    Rizzo, Lorenzo
    Mancini, Valentina
    Greco, Rosa
    Bertani, Giambattista
    Zucchetti, Elisa
    Diral, Elisa
    Nichelatti, Michele
    Veronese, Silvio Marco
    Grillo, Giovanni
    Cairoli, Roberto
    BLOOD, 2020, 136
  • [29] A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML
    Cai, Sheng F.
    Huang, Ying
    Lance, Jennie R.
    Mao, Hsiaoyin Charlene
    Dunbar, Andrew J.
    McNulty, Samantha N.
    Druley, Todd
    Li, Yan
    Baer, Maria R.
    Stock, Wendy
    Kovacsovics, Tibor
    Blum, William G.
    Schiller, Gary J.
    Olin, Rebecca L.
    Foran, James M.
    Litzow, Mark
    Lin, Tara
    Patel, Prapti
    Foster, Matthew C.
    Boyiadzis, Michael
    Collins, Robert H.
    Chervin, Jordan
    Shoben, Abigail
    Vergilio, Jo-Anne
    Heerema, Nyla A.
    Rosenberg, Leonard
    Chen, Timothy L.
    Yocum, Ashley O.
    Druggan, Franchesca
    Marcus, Sonja
    Stefanos, Mona
    Druker, Brian J.
    Mims, Alice S.
    Borate, Uma
    Burd, Amy
    Byrd, John C.
    Levine, Ross L.
    Stein, Eytan M.
    BLOOD ADVANCES, 2024, 8 (02) : 429 - 440
  • [30] Cost-effectiveness of Enasidenib versus conventional care for older patients with IDH2-mutant refractory/relapsed AML
    Alhajahjeh, Abdulrahman
    Patel, Kishan K.
    Shallis, Rory M.
    Podoltsev, Nikolai A.
    Kewan, Tariq
    Stempel, Jessica M.
    Mendez, Lourdes
    Huntington, Scott F.
    Stahl, Maximilian
    Goshua, George
    Bewersdorf, Jan Philipp
    Zeidan, Amer M.
    LEUKEMIA & LYMPHOMA, 2025, 66 (03) : 488 - 496
12345